• Genmab set an extraordinary general meeting for Oct. 7, 2026 to vote on 2026 board remuneration.
• Board seeks approval to keep cash fees unchanged versus 2024-2025, including a DKK 600,000 annual base fee for directors.
• Chair would receive 2x base fee cash compensation, deputy chair 1.5x, with additional committee fees.
• Proposal also maintains share-based pay via RSUs at 3x base fee for the chair, 2.5x for other directors.
• Board-backed proposal requires a simple majority vote.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001434265-26-000116), on September 08, 2026, and is solely responsible for the information contained therein.